US4704364A - Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems - Google Patents
Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems Download PDFInfo
- Publication number
- US4704364A US4704364A US06/612,091 US61209184A US4704364A US 4704364 A US4704364 A US 4704364A US 61209184 A US61209184 A US 61209184A US 4704364 A US4704364 A US 4704364A
- Authority
- US
- United States
- Prior art keywords
- blood cells
- human
- reference control
- cells
- red blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/106664—Blood serum or blood plasma standard or control
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent
Definitions
- This invention relates to hematology control compositions, and methods for their use in a reference standard for particle analysis instrumentation of the COULTER® type. More particularly, this invention relates to a three-component system for simulating the three major components of human leukocytes, namely lymphocytes, mononuclear cells and granulocytes, and optionally sub-divisions thereof, which is compatible with known red blood cell and platelet controls.
- Mononuclear cells are single nucleated blood cells which include monocytes and numerous mature and immature forms of lymphocytes and immature myelocytes and erythrocytic blood cells.
- the modified COULTER COUNTER Model S Plus can deliniate mature lymphocytes and polymorphic granuloctyes from the general group of mononuclear cells found in circulating blood under normal and pathological conditions. These circulating mononuclear blood cells include promyelocytes, myelocytes and blast cells as well as monocytes. Since monocytes are the most prevalent mononuclear cell population under normal hemopoietic conditions, the 90 to 160 fL region can be referred to as the monocyte region.
- U.S. Pat. No. 2,656,508 discloses a basic apparatus utilizing the Coulter principle for this purpose.
- U.S. Pat. No. 3,757,213 contains a description of several such devices which incorporate threshold circuitry. Threshold circuitry excludes random amplitude signals caused by noise and background debris of inconsequential particles in the suspension. It may also be used to limit the size range of the particles counted. Adjustable threshold circuits with dials marked off in mathematically related dial settings are in common use.
- electrostatic particle counter should be understood to include, in addition to COULTER COUNTER® instruments, any other type of particle counter which discriminates between particles of various sizes by the use of electronic discriminator circuits ("thresholds") which respond electronically to signals indicative of particle size, mass or particle volume.
- thresholds electronic discriminator circuits
- erythrocyte red blood cell
- leukocyte white blood cell
- thrombocyte platelet
- the material used for checking calibration hereinafter called a control
- the techniques for using a control generally involve counting known populations of particles suspended in a liquid vehicle in the control preparation, which usually is diluted substantially with a diluent prior to counting.
- no control had been developed for use with three sub-groups of leukocytes, namely, lymphocytes, mononuclear cells and granulocytes, since the equipment for automatic counting of these sub-groups had not been developed.
- control product must accurately indicate on a comparative basis what a test sample of fresh blood constitutes with regard to the determinations in question. It is further evident how important it is for the control product to simulate fresh blood, since blood components, such as red blood cells, can hemolyze slowly and undergo changes in size and shape within hours after removal from a blood donor. Similarly, white blood cells suffer degenerative changes.
- Human lymphocytes, mononuclear cells and granulocytes have a specific size distribution range and after stabilization (for example with a fixative, such as formaldehyde), their responsiveness in diluents may not permit proper size discrimination. This would result in an inability to evaluate proper instrument operation.
- Both the upper and lower size limits for each population of leukocytes must be represented in the reference control material.
- the mean cell volume of each leukocyte population in the reference control material should be very close to that of normal human blood. When upper and lower size limits and mean cell volume are thus specified, it becomes a virtual necessity for the volume distribution histogram of the control material to approximate the normal distribution of the fresh human cells.
- This volume distribution must remain relatively constant regardless of the total white cell count and the range of ratios for all three populations representing abnormal low, normal and abnormal high conditions for human leukocytes. Therefore, it is necessary that the preservation process used in the manufacture of the reference control suspension does not cause significant shrinking or swelling of the cells. Also one must be sure that aging of the reference control does not result in deterioration of the volume distribution histogram characteristics or other parameters.
- a further requirement for the leukocyte component in a whole blood reference control for multi-parameter instruments is that the cells must not be completely lysed by the lytic reagent.
- a novel feature of this invention is the preparation of a stable, reproducible hematology control for three populations of white blood cells.
- methods are given for preparing simulated lymphocytes from mammals, for example human erythrocytes, simulated mononuclear cells from avian, for example turkey erythrocytes, and simulated granulocytes from the erythrocytes of fishes, for example the nurse shark (Ginglymostoma cirratum).
- a novel method is included for the preparation of altered red blood cells of a predetermined size within limits, by control of the age of the red blood cell before treatment and the temperature and concentration of the fixing agent.
- the nurse shark (Ginglymostoma cirratum) has erythrocytes (red blood cells) that normally fall into a size range which is slightly larger than human granulocytes, and that these erythrocytes can be altered and fixed so as to be similar in volume distribution to the volume distribution of human granulocytes in whole blood, in order to be useful as a human granulocyte reference control.
- the granulocyte analogue so prepared is stable and reproducible for use as a stand alone reference control, or in trimodal white blood cell compositions which also contain altered and fixed turkey red blood cells to simulate human mononuclear cells, and altered and fixed human red blood cells to simulate human lymphocytes.
- the white blood cell analogues also can be included in a single multiple-analysis hematology reference control which determines not only white blood cell components, but also red blood cell and platelet parameters.
- the ratio and total cell count for the three leukocyte populations can be adjusted to represent pathological as well as normal conditions in human blood.
- the cells treated by the methods disclosed herein and the compositions including such cells provide an excellent system of checks and balances so necessary in hematological determinations.
- FIGS. 1A and 1B comparatively show the leukocyte distribution histograms of a sample made on the COULTER COUNTER Model S Plus automated blood cell counter.
- FIG. 1A shows a histogram developed from a normal blood sample.
- FIG. 1B shows a histogram developed from the hematology control system and method of the present invention.
- the invention has sufficient flexibility to allow the preparation of lymphocyte, mononuclear cell and granulocyte populations which may be larger or smaller than those shown in FIG. 1B.
- the changes in size then can reflect abnormal white blood cell size distributions, which are characteristic of human pathological conditions.
- Any system for automated differential counting of human leukocytes which distinguishes three populations of leukocytes from other cells in the blood on the basis of characteristic size range and volume distribution, requires that the reference control material used as such closely simulate the size range and volume distribution characteristics of the respective cells in normal human blood.
- the problem is to find methods which accurately will produce cells of a given size in reproducible quantities sufficient to be available, as needed for use in controls for automated counting equipment.
- lymphocytes 35 to 90 ⁇ 3 fL
- granulocytes 160 to 450 ⁇ 3 fL.
- monocytes which are classified and counted in the range designated as "mononuclear cells" include monocytes.
- the procedure of this invention allows the treated red blood cells from different sources to match a plurality of threshold settings between about 25 fL and about 700 fL for many types of blood counting instruments.
- the other COULTER COUNTER instruments, with which this invention can be used, are of the Model S and Model S Plus types.
- the COULTER COUNTER Model S counts leukocytes from 25 fL to infinity.
- Other types of COULTER COUNTER Model S Plus instruments count lymphocytes from about 45 fL to about 99 fL and count mononuclear and granulocytes from about 99 fL to infinity.
- U.S. Pat. No. 3,873,467 discloses a control composition for white blood cells using red blood cells stabilized by means of substituting for the blood plasma, a stabilizing media and fixed swollen red blood cells having increased mean cell volume to substitute for all of the leukocytes present. With swelling to approximately 50% greater volume, the specific gravity of the cell is reduced to be in the range of 1.06 to 1.08.
- fixed human red blood cells substitute only for the smaller lymphocyte portion of the white blood cells, and there is commingled with these simulated lymphocytes, larger fixed animal red blood cells, representing the two larger sizes of the white blood cells, namely the mononuclear cells and the granulocytes.
- larger fixed animal red blood cells representing the two larger sizes of the white blood cells, namely the mononuclear cells and the granulocytes.
- the red blood cells from three species of vertebrates are fixed so that they will not be lysed when determining the white blood cell parameters in the same blood control sample.
- the count for each of the three populations may be varied in proportion to one another without effecting a major shift in the original volume distribution.
- the primary methods in this invention for controlling the size of the lymphocyte analogues are proper selection of the size of the non-fixed human red blood cells, the osmolality of the fixing solution and the variation in fixation temperature.
- Shrinking or expansion of the cells by manipulating their osmotic environment prior to fixation has limitations due to criticality of the fixation process required to maintain stability of the altered cells during the lysing of the untreated human red blood cells in the mixture.
- red blood cells it is necessary to treat such red blood cells in a manner which allows them to be shrunken or swollen without excessive cell association or hemolysis to approximate the size needed.
- the present invention embodies a composition prepared by mixing a suspension of fixed human red blood cells to simulate human lymphocytes, fixed red blood cells from turkeys to simulate human mononuclear cells, and a suspension of stabilized red blood cells from nurse sharks to simulate human granulocytes, all assembled in a liquid media and in such proportions as to provide a single composition to simulate human white cells (See FIG. 1B).
- This leukocyte analogue composition is then comingled with human red blood cells to be lysed, and stabilized platelets or platelet analogues to provide a single multiple-analysis reference control.
- the ratio of the simulated white blood cell population can be adjusted to represent abnormal low, normal and abnormal high conditions without affecting the size distribution of each type of simulated white blood cell. Modification of the preparative steps will allow the production of particles which represent different types of white blood cells which are characteristic of abnormal human white blood cell conditions.
- the media is prepared according to the teachings of U.S. Pat. Nos. 4,299,726 and 4,358,394; and the platelets are stabilized according to any one of the methods described in U.S. Pat. Nos. 4,264,470, 4,389,490, or 4,405,719; all of these patents are assigned to Coulter Electronics, Inc.
- This invention includes the selection and specific treatment steps for red blood cells from one or more animal sources. Generally, it is not possible to shrink or swell red blood cells more than about 30% to 50% total. Therefore, it is necessary to start with cells which approximate each population as shown in FIGS. 1A and 1B.
- the essence of the present invention lies in the discovery that red blood cells from the sources stated above have suitable characteristics to allow them to be shrunken or swollen and fixed without excessive cell association and hemolysis to approximate the size of the corresponding human blood cell with a narrow range of mean cell volume.
- the red blood cells are suspended in an anticoagulant, such as an alkali metal salt of ethylenediaminetetraacetic acid (EDTA) dissolved in a physiological saline solution (sodium chloride).
- an anticoagulant such as an alkali metal salt of ethylenediaminetetraacetic acid (EDTA) dissolved in a physiological saline solution (sodium chloride). It is envisioned that other anticoagulants and salts will do, as long as they do not cause undue hemolysis or cell association.
- the anticoagulant will affect the size of the blood cell as a function of concentration and the time of exposure. For example, cells suspended in 2.5 mM to 10 mM EDTA will retain the same size for up to 24 hours after collection. At a concentration greater than 10 mM EDTA, for example 20 mM, the cells will begin to swell in less than 24 hours. After 24 hours, the size of the cell increases with the concentration of EDTA as well as the exposure time. The maintenance or increase in cell size as a function EDTA concentration and time of exposure, can be preserved by fixation. It is assumed that EDTA can significantly disrupt cell membrane structure and this disruption becomes magnified as a function of time. Thus, it is possible to manipulate cell size by controlling the concentration of anticoagulant and time of exposure prior to fixation.
- red blood cells which must be shrunk prior to fixation. At the time of fixation, it is important to maintain hypertonicity to prevent any swelling of the cells.
- the effective final concentration of the salt solution should be in a range which is equal to and up to four times greater than that of normal serum, depending on the degree of shrinking required to simulate a specific white blood cell population.
- the addition of a fixing agent adds to the tonicity (osmolality) of the fixing solution.
- Fixing of the shrunken cells is important to toughen the cell membranes and to prevent biodegration of the membranes. This is accomplished by contacting the suspension of the cells with a solution of an organic aldehyde, including monoaldehydes such as formaldehyde, or dialdehydes such as glutaraldehyde.
- Glutaraldehyde is the preferred aldehyde, since it reacts more speedily than formaldehyde.
- Glutaraldehyde can be added in higher concentrations than the final concentration, so long as the final concentration thereof is in the range of about 0.1% to 1.0%.
- the final concentration of formaldehyde is 2.5% to 10%; the preferred concentration is 5%.
- the only practical limitations on selection of an appropriate aldehyde and concentration thereof are elimination of undue cell association and hemolysis and potential undesirable electrolytic effects.
- the specific conditions recommended for each of the leukocyte components are given in each of the examples subsequently set forth.
- red blood cells with the narrowest distribution width are obtained with any kind of blood using fresh cells, or cells aged for not more than four days after phlebotomy, with a low concentration of the anticoagulent, used for collecting the fresh blood.
- a higher concentration of EDTA will result in larger non-fixed as well as fixed cells, which might not fit the criteria for the paricular size range sought.
- the blood cells are added to a chilled hypertonic salt solution containing glutaraldehyde.
- the reduced temperature has been shown to provide a qualitatively different cell as measured on a sizing apparatus such as a COULTER COUNTER analyzer.
- a qualitative difference includes a lower mean cell volume compared to fixing at room temperature. This difference, however, might not be evident until treatment of the fixed cell with a lysing agent as LYSE S® II reagent in ISOTON® II diluent.
- LYSE S and ISOTON are U.S. Registered Trademarks of Coulter Electronics, Inc.
- the cells After fixation, the cells are allowed to settle by gravity, are separated from the liquid phase, then are washed with a phosphate buffered saline solution and placed in a storage solution.
- the formulation for the diluent is the same for measuring all three components of the leukocyte analogue.
- the preferred formula for this diluent, as well as the formula for the lysing agent to be used for lysing the untreated red blood cells to be added later to the white blood cell assembly, are given below:
- the media for the hematological reference controls having stability up to six months includes lactose, fungicides and antibiotics, and supplementary agents such as purine nucelosides, bile salt, and cholic acid derivatives, phenothiazine compounds and the salts thereof having antihistamine properties, and 4-aminobenzoic acid esters and derivatives and their salts having aesthetic properties, or combinations thereof.
- lactose fungicides and antibiotics
- supplementary agents such as purine nucelosides, bile salt, and cholic acid derivatives, phenothiazine compounds and the salts thereof having antihistamine properties, and 4-aminobenzoic acid esters and derivatives and their salts having aesthetic properties, or combinations thereof.
- lymphocyte analogue human erythrocytes are fixed with glutaraldehyde, following the procedure detailed below in Example 1, and then included in a predetermined amount in reference controls and calibrators, together with the mononuclear cell analogue (Example ) and the granulocyte analogue (Example 3), or in whole blood controls containing, in addition to the lymphocyte analogues, washed red blood cells, or washed red blood cells and platelets.
- Fresh human red blood cells must be washed to remove donor specific plasma proteins. This will reduce the probability of cell agglutination when mixing red cells from multiple blood cell donors.
- a lytic agent to a diluent designed for the Model S Plus COULTER COUNTER series (e.g. Model S Plus II, III, and IV) will show similar results.
- the formulation for these diluents and lysing agents are disclosed hereinafter.
- a totally fixed human red blood cell e.g. 48 hour fixation
- Over-fixation of red blood cells with glutaraledehyde is noted after 72 to 96 hours by a drop in particle size which is independent of the effect of above mentioned red blood cell lytic agents on 48 hour fixed human red blood cells.
- the desired amount of fixation will produce cells which are counted in the range of about 35 to 90 ⁇ 3 fL using a COULTER COUNTER Model S Plus type analyzer.
- Human mononuclear cells are leukocytes which are intermediate in size between lymphocytes and granulocytes, and are counted in the size range, or monocyte region of between 90 and 160 ⁇ 3 fL. These cells are larger than fixed human red blood cells.
- Avian red blood cells are larger than fixed human red blood cells, and close to the size of human mononuclear cells.
- fowl red blood cells such as goose, chicken, duck, and preferably turkey red blood cells, closely match the size and shape of human mononuclear cells, and lend themselves to the aldehyde stabilization process.
- These stabilized "simulated" monocyte cells provide a satisfactory substitute for human mononuclear cells in our control composition.
- Example 2 A process for preparing a mononuclear cell analogue from turkey red blood cells is detailed in Example 2.
- Human granulocytes represent the largest size of the three leukocyte populations now counted by the COULTER COUNTER Model S Plus automated cell counter. The granulocytes are counted in the size range between about 160 and 450 ⁇ 3 fL.
- non-human vertebrates which are known to have red blood cells in the desired size range for human granulocytes include other fishes, particularly members of the shark family and reptiles such as alligators. All of these non-human vertebrates have nucleated red blood cells which could be used. However, considerations, such as availability in quantity at reasonable expense, must be considered. Red blood cells of the nurse shark are readily available in quantity. The red blood cells of alligators tend to be less readily available, because alligators are presently a "protected" species by government authorities.
- the cells of both alligators and nurse sharks are nucleated, but the presence of a nucleus is not essential for their use as a substitute for human white blood cells for the purposes of this invention.
- the presence of the nucleus in the shark red blood cell is not detrimental, inasmuch as the cells are stabilized with a cross-linking agent, such as glutaraldehyde, which prevents the cell membrane and cytoplasm from being stripped from the nucleus during lysis.
- a cross-linking agent such as glutaraldehyde
- a standardized and stabilized red blood cell composition from the nurse shark provides a suitable reference control which is useful in the enumeration of human granulocytes by automated means using instruments operating under the Coulter principle, or by various microscopic techniques, such as illumination or phase contrast methods.
- nurse shark erythrocytes are altered and stabilized to simulate a human granulocyte analogue with respect to volume in femtoliters (fL) and count as 1 ⁇ 10 3 per microliter (uL).
- fL femtoliters
- uL microliter
- the product is designed to behave in a manner which as closely as possible simulates fresh human granulocytes.
- the product is designed to possess a feature not found in fresh normal granulocytes, that is a high level of stability of the parameters measured by the cell counters in which it is used.
- Example 3 is a specific example of preferred reagents and techniques for treating the shark cells, it being understood that the formulations are only illustrative. The reagents and/or techniques described can also be applicable to red blood cells from animals other than sharks. Other ingredients and proportions can be employed, in accordance with this disclosure. However, the size of the cell in a non-lytic solution, as in a buffer, may not visually show the entire effect of the treatment employed in this invention. The process requires the control of:
- red blood cells with the narrowest distribution width are obtained using fresh cells, or cells aged for not more than four days after phlebotomy, with a low concentration of EDTA.
- Using a higher concentration of EDTA on cells aged more than 24 hours will result in larger non-fixed as well as fixed cells which might not fit the 160 to 450 ⁇ 3 femtoliter criteria for human granulocytes.
- Maintaining the fixing solution at 0° to 10° C., preferably 4° C., prior to and after the addition of chilled anticoagulated blood also will result in a smaller blood cell for use in this invention.
- Nurse shark cells treated by the above method are highly stable when used in the reference control composition of this invention.
- the simulated granulocytes can be used in a stand alone granulocyte control, or in a composite and unitary control standard which measures other blood parameters. More particularly, this novel granulocyte control is used in combination with compatible controls for other leukocyte components such as lymphocytes and mononuclear cells, to furnish a leukocyte control, which in turn is used in combination with reference controls for red blood cells and platelet parameters.
- Example 1 to 3 give detailed instructions for one method of preparing each of the three components of the leukocyte reference control.
- Example 4 shows an assembly of the three leukocyte populations. These procedures are controlled carefully throughout in order to make sure that the cells are not damaged and that the fixed cells become substantially totally resistant to the usual red blood cell lytic reagent. It will be understood that the formulations are only illustrative, and other ingredients and proportions may be employed, in accordance with this disclosure.
- anticoagulants can be used, as determined by those skilled in the art.
- Standard ACD acid-citrate-dextrose
- Disodium EDTA ethylenediamine tetraacetate
- Stabilizing media (liter formulation), as above set forth and with reference to U.S. Pat. No. 4,299,726.
- step 4 Add a measured amount of the fixative of step 3 to the washed red blood cell suspension to obtain a final glutaraldehyde concentration of 0.1% to 1.0%, and mix for about 20 minutes. Transfer to sealed containers which are rolled slowly for 12 to 72 hours.
- the fixed cells can be stored for a time period of up to about six months.
- the final concentration of formaldehyde is 2.5% to 10%.
- the time required for fixation with formaldehyde is longer than with glutaraldehyde.
- One or more of the following anticoagulants can be used in suitable quantity, as determined by one skilled in the art.
- Standard ACD acid-citrate-dextrose
- Disodium EDTA ethylenediamine tetraacetate
- Stabilizing media (liter formulation), as above set forth and with reference to U.S. Pat. No. 4,299,726.
- a glutaraldehyde fixing reagent having a glutaraldehyde content of about 1.0 to 10.0% by adding a commercial 25% glutaraldehyde product to the Turkey Erythrocyte Washing and Diluting Solution (TEWDS). The preferred concentration is 5%.
- the fixed cells can be stored for a time period of up to about six months.
- Disodium EDTA ethylenediamine tetraacetate
- the shark ordinarily has a high concentration of urea in its blood which helps to maintain osmotic equilibrium of the red blood cells. For this reason urea is added to the subassembly in order to mimic the resulting osmotic conditions.
- Stabilizing media (liter formulation), as above set forth.
- EDTA ethylenediamine tetraacetic acid
- the glutaraldehyde fixation processing of blood can take place within four days if it is stored in less than 20 mM EDTA; and fixation can take place in less than one day if stored in 20 to 30 mM of EDTA.
- a glutaraldehyde fixing solution which has a glutaraldehyde concentration of 1.0%, and an osmolality of 1000 to 4000 mOs/kg (preferred concentration is 3000 ⁇ 100 mOs/kg).
- the pH range is 4.5 to 8; preferred pH is 4.0 ⁇ 0.5.
- the fixed cells can be stored for a time period of up to about six months.
- This sub-assembly can be stored for up to about six months.
- untreated human blood cells stabilized by suspension in media described earlier, can satisfactorily provide the red blood cell component of the subject composition.
- the untreated red blood cells are hemolyzed readily in the prior operational step for the white blood cell count and subsequent hemoglobin determination.
- Suspensions of untreated human red blood cells, simulated white blood cells, and stabilized or simulated platelets are mixed in such proportion that the final red blood cell, white blood cell and platelet counts, as well as hemoglobin content and hematocrit fall in the range considered normal for human blood.
- Stabilized platelets are furnished by methods known in the art. Useful methods include:
- a fixative-stabilizing composition containing a glutaraldehyde concentration of 0.1% to 5% and a non-ionic surfactant which is a mixture of ethoxylates of certain isomeric linear alcohols, as is more fully described in U.S. Pat. No. 4,389,490.
- a human platelet analogue comprising goat erythrocytes stabilized, combined and blended as necessary to have a size range and volume distribution close to that of human platelets, as is described in U.S. Pat. No. 4,264,470.
- platelets are used as controls for procedures that include unfixed red blood cells which are to be lysed, it is necessary to use fixed cells as a leukocyte analogue.
- fixed cells can be prepared, for example, by the method described in U.S. Pat. No. 4,179,398.
- the values for each of the hemotological parameters can be varied to represent abnormal low and abnormal high conditions.
- the white blood cell count in normal blood is 5,000 to 11,000 per microliter (uL) with a lymphocyte value of 20 to 40%, mononuclear cell value of less than 10% and a granulocyte value of 60 to 80%.
- the normal range in human blood for red blood cells is 4,000,000 to 5,000,000 cells per microliter.
- the normal homoglobin value is 12 to 16 grams/100 ml.
- the term "hematocrit" is defined as the ratio of volume of packed red blood cells to the volume of whole blood.
- the normal ratio in humans is about 45%.
- the mean corpuscular volume is the ratio of the volume of packed red blood cells in ml per liter of blood to red blood cells in millions per microliter.
- the mean corpuscular hemoglobin concentration is an index indicating the mean or average weight of hemoglobin per 100 ml of packed red blood cells in terms of percent.
- the mean corpuscular hemoglobin is the ratio of hemoglobin content, in grams per liter, to red blood cells, in millions per microliter.
- control product must accurately indicate on a comparative basis what a test sample of fresh whole blood constitutes with regard to all the above determinations. It is evident how important it is for the control product to simulate normal human cells in an anticoagulant.
- This invention primarily is directed to a hematology reference control solution, the white cell control portions thereof consisting of three types of fixed red blood cells of determined size distribution for checking the predetermined lower and upper threshold settings for each class or subclass of leukocytes, as set electrically in the particle analyzing instrument.
- the upper and lower electronic threshold setting for each of the classes of leukocytes are checked by the relationship of the particle counts of each of the discriminator regions compared to known values.
- Each type of simulated leukocyte must maintain size independent of total cell count and independent of its proportionality to one or more types of simulated leukocyte populations.
- the red blood cell control portions thereof consist of stabilized human red blood cells in a stabilizing media, such as is described hereinabove and in U.S. Pat. No. 4,299,726 in column 7, which are to be lysed as stated hereinabove. These red blood cells are added in such proportions that the final red blood cell count, as well as hemoglobin content and hematocrit fall in the range considered normal for human blood as stated hereinabove. These added red blood cells retain their ability to respond to a lysing reagent by stromatolization.
- the cells treated by the method disclosed herein provide an excellent system of checks and balances so necessary in hematological determinations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/612,091 US4704364A (en) | 1984-05-18 | 1984-05-18 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
AU43527/85A AU592754B2 (en) | 1984-05-18 | 1985-05-07 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
PCT/US1985/000840 WO1985005450A1 (en) | 1984-05-18 | 1985-05-07 | Hematology control compositions for three populations of leukocytes: and methods for their preparation and use in whole blood control systems |
JP60502217A JP2557837B2 (ja) | 1984-05-18 | 1985-05-07 | 白血球の3つの母集団についての血液学規準コントロール流体懸濁物およびその製造方法 |
KR1019860700028A KR920010294B1 (ko) | 1984-05-18 | 1985-05-07 | 백혈구의 3개의 모 집단에 대한 혈액학 콘트롤 조성물 · 및 그 조제방법과 전혈액 조절체계에 있어서의 사용방법 |
DE8585902765T DE3586619T2 (de) | 1984-05-18 | 1985-05-07 | Haematologische zusammensetzungen als referenz fuer drei populationen von leukocyten, verfahren zu deren herstellung und deren verwendung in ganzbluttestverfahren. |
EP85902765A EP0181393B1 (en) | 1984-05-18 | 1985-05-07 | Hematology control compositions for three populations of leukocytes, and methods for their preparation and use in whole blood control systems |
CA000481779A CA1249208A (en) | 1984-05-18 | 1985-05-17 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
ES543228A ES8609719A1 (es) | 1984-05-18 | 1985-05-17 | Una suspension fluida de control de referencia para hemato- logia |
US07/510,376 US5380664A (en) | 1984-05-18 | 1990-04-17 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/612,091 US4704364A (en) | 1984-05-18 | 1984-05-18 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11567187A Division | 1984-05-18 | 1987-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
US4704364A true US4704364A (en) | 1987-11-03 |
Family
ID=24451685
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/612,091 Expired - Lifetime US4704364A (en) | 1984-05-18 | 1984-05-18 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
US07/510,376 Expired - Fee Related US5380664A (en) | 1984-05-18 | 1990-04-17 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/510,376 Expired - Fee Related US5380664A (en) | 1984-05-18 | 1990-04-17 | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems |
Country Status (9)
Country | Link |
---|---|
US (2) | US4704364A (ja) |
EP (1) | EP0181393B1 (ja) |
JP (1) | JP2557837B2 (ja) |
KR (1) | KR920010294B1 (ja) |
AU (1) | AU592754B2 (ja) |
CA (1) | CA1249208A (ja) |
DE (1) | DE3586619T2 (ja) |
ES (1) | ES8609719A1 (ja) |
WO (1) | WO1985005450A1 (ja) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017330A1 (en) * | 1992-02-24 | 1993-09-02 | Coulter Corporation | Hematology control composition for leukocyte analogs; and methods for their preparation and use |
WO1993017329A1 (en) * | 1992-02-24 | 1993-09-02 | Coulter Corporation | Suspension media for hematological composition and method for its use |
US5262327A (en) * | 1991-05-09 | 1993-11-16 | Streck Laboratories, Inc. | White blood cell hematology control |
US5459073A (en) * | 1991-05-08 | 1995-10-17 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
US5460797A (en) * | 1991-05-08 | 1995-10-24 | Streck Laboratories, Inc. | Method for fixing tissues and cells for analysis using oxazolidine compounds |
WO1996034291A1 (en) * | 1995-04-28 | 1996-10-31 | Coulter International Corp. | Quality control method of hematology instruments |
US5672474A (en) * | 1991-05-09 | 1997-09-30 | Streck Laboratories, Inc. | White blood cell hematology control |
US5736402A (en) * | 1994-10-12 | 1998-04-07 | Research & Diagnostics Systems, Inc. | Reticulocyte assay control |
US5811303A (en) * | 1997-04-01 | 1998-09-22 | Streck Laboratories, Inc. | Quantitative buffy coat control composition |
US5849517A (en) * | 1991-05-08 | 1998-12-15 | Streck Laboratories, Inc. | Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same |
US5858790A (en) * | 1996-06-26 | 1999-01-12 | Abbott Laboratories | Hematology reference control and method of preparation |
US5863799A (en) * | 1995-10-04 | 1999-01-26 | Hycor Biomedical, Inc. | Erythrocyte sedimentation rate control |
US5895760A (en) * | 1997-02-04 | 1999-04-20 | Hycor Biomedical, Inc. | Erythrocyte sedimentation rate control |
US5994139A (en) * | 1998-04-07 | 1999-11-30 | Coulter International Corp. | Stable hematology control composition and method of use |
US6124089A (en) * | 1999-04-30 | 2000-09-26 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
US6146901A (en) * | 1997-06-16 | 2000-11-14 | Hematronix, Inc. | Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition |
US6159682A (en) * | 1999-04-30 | 2000-12-12 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
US6200500B1 (en) | 1999-08-20 | 2001-03-13 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6221668B1 (en) | 1999-08-20 | 2001-04-24 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6362003B1 (en) | 1992-02-24 | 2002-03-26 | Coulter Corporation | Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof |
US6444471B1 (en) | 1999-10-18 | 2002-09-03 | Research & Diagnostic Systems, Inc. | Reticulocyte containing complete blood control |
US6509192B1 (en) | 1992-02-24 | 2003-01-21 | Coulter International Corp. | Quality control method |
US6531321B1 (en) | 2000-09-15 | 2003-03-11 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
EP1307723A1 (en) * | 2000-06-12 | 2003-05-07 | Hematronix, Inc. | Hematology composition using preserved white blood cells |
US6569682B2 (en) | 2001-07-27 | 2003-05-27 | Coulter International Corp. | Hematology control product with increased closed vial stability |
US6632676B1 (en) * | 1999-09-24 | 2003-10-14 | Clinical Diagnostic Solutions | Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells |
US6653137B2 (en) | 2001-12-03 | 2003-11-25 | Streck Laboratories Inc. | Hematology reference control |
US6653063B2 (en) | 2000-06-12 | 2003-11-25 | Hematronix, Inc. | Hematology composition using preserved white blood cells in combination with source particles to simulate native white blood cells and method of making same |
US6723563B2 (en) | 2001-12-03 | 2004-04-20 | Streck Laboratories Inc. | Hematology reference control |
US6759246B1 (en) | 2001-11-30 | 2004-07-06 | Research & Diagnostic Systems, Inc. | Hematology control composition including lymphocyte analogs and method for preparation and use |
US20050074894A1 (en) * | 2003-10-02 | 2005-04-07 | Beckman Coulter, Inc. | Reference control for optical measurement of nucleated red blood cells of a blood sample |
US20050079623A1 (en) * | 2003-10-12 | 2005-04-14 | Beckman Coulter, Inc. | Method of using a reference control composition for measurement of nucleated red blood cells |
US20050136409A1 (en) * | 2003-12-19 | 2005-06-23 | Beckman Coulter, Inc. | Hematology controls for reticulocytes and nucleated red blood cells |
US20050227359A1 (en) * | 2004-04-07 | 2005-10-13 | Beckman Coulter, Inc. | Reference control containing a nucleated red blood cell component |
US20050255447A1 (en) * | 2004-05-13 | 2005-11-17 | Beckman Coulter, Inc. | Hematology reference control containing an immature granulocyte component |
US20060194191A1 (en) * | 2005-02-25 | 2006-08-31 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Processing method for the long-term stabilization of biological red blood cell volume |
US20060223187A1 (en) * | 2005-04-04 | 2006-10-05 | Bio-Rad Laboratories, Inc., A Corporation Of The State Of Delaware | Preparation of platelet analogs |
US20070218558A1 (en) * | 2006-03-16 | 2007-09-20 | Beckman Coulter, Inc. | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells |
US20080113438A1 (en) * | 2006-11-14 | 2008-05-15 | Beckman Coulter, Inc. | Hematology Linearity Control Composition, System and Method of Use |
US20080293145A1 (en) * | 2007-05-24 | 2008-11-27 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Single population of simulated leukocyte granules, calibrators comprising the same and methods of preparing the same |
US20090258338A1 (en) * | 2008-04-15 | 2009-10-15 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Simulated 5-part differential leukocyte granules, the method for preparing the same and control products and calibrators comprising the same |
CN100577797C (zh) * | 2005-07-04 | 2010-01-06 | 深圳迈瑞生物医疗电子股份有限公司 | 制备人淋巴细胞模拟物的方法 |
CN101887059A (zh) * | 2009-05-11 | 2010-11-17 | 深圳迈瑞生物医疗电子股份有限公司 | 嗜酸性粒细胞模拟物、制备方法及全血质控物 |
CN1891815B (zh) * | 2005-07-04 | 2010-12-08 | 深圳迈瑞生物医疗电子股份有限公司 | 制备细胞模拟物的方法 |
CN102419365A (zh) * | 2011-08-24 | 2012-04-18 | 山东兰桥医学科技有限公司 | 一种三分类血液分析仪用标准物质的制备方法 |
CN103454410A (zh) * | 2012-05-30 | 2013-12-18 | 桂林优利特医疗电子有限公司 | 血液测试仪用生物安全质控物及其制备方法 |
WO2018022991A1 (en) | 2016-07-29 | 2018-02-01 | Streck, Inc. | Suspension composition for hematology analysis control |
CN110770587A (zh) * | 2017-05-08 | 2020-02-07 | 拜克门寇尔特公司 | 用于裂解红细胞的组合物和方法 |
CN114657125A (zh) * | 2022-04-29 | 2022-06-24 | 中国科学院海洋研究所 | 鲨鱼单个核细胞的分离方法、鲨鱼稀释液及其用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4346018A (en) * | 1980-06-16 | 1982-08-24 | Coulter Electronics, Inc. | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes |
US4485175A (en) * | 1983-01-03 | 1984-11-27 | Coulter Electronics, Inc. | Method for three-volume differential determination of lymphocyte, monocyte and granulocyte populations of leukocytes |
KR100303608B1 (ko) | 1997-05-22 | 2001-11-22 | 박호군 | 혈구세포자동인식방법및장치 |
NZ504405A (en) | 1997-10-08 | 2002-09-27 | Theragem Inc | Method for killing bacteria or fungi comprising contacting them mammalian haemoglobin proteins and fragments thereof |
AU9017298A (en) | 1997-10-08 | 1999-04-27 | Theragem, Inc. | Reptilian-derived peptides for the treatment of microbial infection |
DE19836559A1 (de) | 1998-08-12 | 2000-03-23 | Antigen Gmbh | Gefäß zur Entnahme von Blut |
EP1516181A2 (en) * | 2002-05-07 | 2005-03-23 | Becton Dickinson and Company | Container for taking samples and in particular blood samples |
US8597190B2 (en) | 2007-05-18 | 2013-12-03 | Optiscan Biomedical Corporation | Monitoring systems and methods with fast initialization |
CA2702113A1 (en) * | 2007-10-11 | 2009-04-16 | Optiscan Biomedical Corporation | Synchronization and configuration of patient monitoring devices |
US20100086962A1 (en) * | 2008-10-08 | 2010-04-08 | Streck, Inc. | Hematology controls and methods |
CN103336110B (zh) * | 2013-06-18 | 2014-08-13 | 南京普朗医疗设备有限公司 | 一种全血质控物及其制备方法 |
EP3270161B1 (en) * | 2015-03-13 | 2023-08-09 | Sony Group Corporation | Sample for electrical characteristic measurement, electrical characteristic measuring method, and electrical characteristic measuring device |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2656508A (en) * | 1949-08-27 | 1953-10-20 | Wallace H Coulter | Means for counting particles suspended in a fluid |
US3519572A (en) * | 1966-10-03 | 1970-07-07 | Pfizer & Co C | Blood control |
US3558522A (en) * | 1969-03-05 | 1971-01-26 | Baxter Laboratories Inc | Hematology control standard comprising washed red blood cells and synthetic latex particles |
US3574137A (en) * | 1969-02-25 | 1971-04-06 | Pfizer | Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium |
US3632735A (en) * | 1970-03-11 | 1972-01-04 | Pfizer & Co C | Method of stabilizing fowl red blood cells for use in hematology control compositions |
US3757213A (en) * | 1970-05-25 | 1973-09-04 | Coulter Electronics | Ntrol particle size analyzing apparatus and method using threshold level co |
US3873467A (en) * | 1974-02-01 | 1975-03-25 | United Medical Lab Inc | Hematologic reference control |
US4179398A (en) * | 1977-03-21 | 1979-12-18 | ICN Medical Laboratories, Inc. | Platelet control composition |
US4213876A (en) * | 1978-08-22 | 1980-07-22 | Coulter Electronics, Inc. | Multi-purpose blood diluent for use in electronic blood analysis instrumentation |
US4219440A (en) * | 1979-06-06 | 1980-08-26 | Coulter Electronics, Inc. | Multiple analysis hematology reference control reagent and method of making the same |
US4264470A (en) * | 1979-05-07 | 1981-04-28 | Coulter Electronics, Inc. | Selecting goat erythrocytes to simulate human platelets in hematologic reference controls |
US4299726A (en) * | 1979-05-07 | 1981-11-10 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor |
US4302355A (en) * | 1977-08-01 | 1981-11-24 | Warner-Lambert Company | Platelet reference control |
US4324686A (en) * | 1979-06-11 | 1982-04-13 | R & D Systems, Inc. | Hematology control composition and methods for its use |
US4338564A (en) * | 1979-06-11 | 1982-07-06 | R & D Systems, Inc. | Hematology control composition and methods for its use |
US4358394A (en) * | 1979-05-07 | 1982-11-09 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability |
US4389490A (en) * | 1981-05-29 | 1983-06-21 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; and diluents thereof |
US4405719A (en) * | 1981-05-29 | 1983-09-20 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures |
US4435507A (en) * | 1980-07-08 | 1984-03-06 | Stenkvist Bjoern G | Process and device for preparation of cell samples for cytological tests |
US4436821A (en) * | 1982-04-12 | 1984-03-13 | Streck Laboratories, Inc. | Simulated human platelets from red blood cells |
US4528274A (en) * | 1982-07-06 | 1985-07-09 | Coulter Electronics, Inc. | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3406121A (en) * | 1965-10-01 | 1968-10-15 | Dade Reagents Inc | Blood cell counting standard and method of preparing the same |
US3973913A (en) * | 1976-01-29 | 1976-08-10 | Louderback Allan Lee | Blood control standard |
US4099917A (en) * | 1977-07-21 | 1978-07-11 | Technicon Instruments Corporation | Process for preparing a cell suspension from blood for discrimination of white blood cells and platelets from other blood particles |
US4250051A (en) * | 1978-12-26 | 1981-02-10 | Coulter Electronics, Inc. | Preservative for use in calibrator compositions for blood analysis |
US4346018A (en) * | 1980-06-16 | 1982-08-24 | Coulter Electronics, Inc. | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes |
US4485175A (en) * | 1983-01-03 | 1984-11-27 | Coulter Electronics, Inc. | Method for three-volume differential determination of lymphocyte, monocyte and granulocyte populations of leukocytes |
US4575490A (en) * | 1984-02-29 | 1986-03-11 | Technicon Instruments Corporation | One step method for sphering and fixing whole blood erythrocytes |
-
1984
- 1984-05-18 US US06/612,091 patent/US4704364A/en not_active Expired - Lifetime
-
1985
- 1985-05-07 DE DE8585902765T patent/DE3586619T2/de not_active Expired - Lifetime
- 1985-05-07 EP EP85902765A patent/EP0181393B1/en not_active Expired - Lifetime
- 1985-05-07 WO PCT/US1985/000840 patent/WO1985005450A1/en active IP Right Grant
- 1985-05-07 JP JP60502217A patent/JP2557837B2/ja not_active Expired - Lifetime
- 1985-05-07 AU AU43527/85A patent/AU592754B2/en not_active Ceased
- 1985-05-07 KR KR1019860700028A patent/KR920010294B1/ko not_active IP Right Cessation
- 1985-05-17 ES ES543228A patent/ES8609719A1/es not_active Expired
- 1985-05-17 CA CA000481779A patent/CA1249208A/en not_active Expired
-
1990
- 1990-04-17 US US07/510,376 patent/US5380664A/en not_active Expired - Fee Related
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2656508A (en) * | 1949-08-27 | 1953-10-20 | Wallace H Coulter | Means for counting particles suspended in a fluid |
US3519572A (en) * | 1966-10-03 | 1970-07-07 | Pfizer & Co C | Blood control |
US3574137A (en) * | 1969-02-25 | 1971-04-06 | Pfizer | Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium |
US3558522A (en) * | 1969-03-05 | 1971-01-26 | Baxter Laboratories Inc | Hematology control standard comprising washed red blood cells and synthetic latex particles |
US3632735A (en) * | 1970-03-11 | 1972-01-04 | Pfizer & Co C | Method of stabilizing fowl red blood cells for use in hematology control compositions |
US3757213A (en) * | 1970-05-25 | 1973-09-04 | Coulter Electronics | Ntrol particle size analyzing apparatus and method using threshold level co |
US3873467A (en) * | 1974-02-01 | 1975-03-25 | United Medical Lab Inc | Hematologic reference control |
US4179398A (en) * | 1977-03-21 | 1979-12-18 | ICN Medical Laboratories, Inc. | Platelet control composition |
US4302355A (en) * | 1977-08-01 | 1981-11-24 | Warner-Lambert Company | Platelet reference control |
US4213876A (en) * | 1978-08-22 | 1980-07-22 | Coulter Electronics, Inc. | Multi-purpose blood diluent for use in electronic blood analysis instrumentation |
US4264470A (en) * | 1979-05-07 | 1981-04-28 | Coulter Electronics, Inc. | Selecting goat erythrocytes to simulate human platelets in hematologic reference controls |
US4299726A (en) * | 1979-05-07 | 1981-11-10 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor |
US4358394A (en) * | 1979-05-07 | 1982-11-09 | Coulter Electronics, Inc. | Process for preparing whole blood reference controls having long term stability |
US4219440A (en) * | 1979-06-06 | 1980-08-26 | Coulter Electronics, Inc. | Multiple analysis hematology reference control reagent and method of making the same |
US4324686A (en) * | 1979-06-11 | 1982-04-13 | R & D Systems, Inc. | Hematology control composition and methods for its use |
US4338564A (en) * | 1979-06-11 | 1982-07-06 | R & D Systems, Inc. | Hematology control composition and methods for its use |
US4435507A (en) * | 1980-07-08 | 1984-03-06 | Stenkvist Bjoern G | Process and device for preparation of cell samples for cytological tests |
US4389490A (en) * | 1981-05-29 | 1983-06-21 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; and diluents thereof |
US4405719A (en) * | 1981-05-29 | 1983-09-20 | Coulter Electronics, Inc. | Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures |
US4436821A (en) * | 1982-04-12 | 1984-03-13 | Streck Laboratories, Inc. | Simulated human platelets from red blood cells |
US4528274A (en) * | 1982-07-06 | 1985-07-09 | Coulter Electronics, Inc. | Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes |
Non-Patent Citations (7)
Title |
---|
Dorland s Illustrated Medical Dictionary, 24th Edit., W. B. Saunders Co., Philadelphia. * |
Dorland's Illustrated Medical Dictionary, 24th Edit., W. B. Saunders Co., Philadelphia. |
Stedman s Medical Dictionary, Williams & Wilkins Company, Baltimore. * |
Stedman's Medical Dictionary, Williams & Wilkins Company, Baltimore. |
Taber s Cyclopedic Medical Dictionary, 8th Edit., F. A. Davis Company, Philadelphia. * |
Taber's Cyclopedic Medical Dictionary, 8th Edit., F. A. Davis Company, Philadelphia. |
U.S. Ser. No. 454,926, Ledis et al., Jan. 1983. * |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459073A (en) * | 1991-05-08 | 1995-10-17 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
US5849517A (en) * | 1991-05-08 | 1998-12-15 | Streck Laboratories, Inc. | Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same |
US5811099A (en) * | 1991-05-08 | 1998-09-22 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
US5460797A (en) * | 1991-05-08 | 1995-10-24 | Streck Laboratories, Inc. | Method for fixing tissues and cells for analysis using oxazolidine compounds |
US5981282A (en) * | 1991-05-09 | 1999-11-09 | Streck Laboratories, Inc. | White blood cell hematology control |
US5672474A (en) * | 1991-05-09 | 1997-09-30 | Streck Laboratories, Inc. | White blood cell hematology control |
US5677145A (en) * | 1991-05-09 | 1997-10-14 | Streck Laboratories, Inc. | White blood cell hematology control |
US5731205A (en) * | 1991-05-09 | 1998-03-24 | Streck Laboratories, Inc. | White blood cell hematology control |
US5262327A (en) * | 1991-05-09 | 1993-11-16 | Streck Laboratories, Inc. | White blood cell hematology control |
US5320964A (en) * | 1992-02-24 | 1994-06-14 | Coulter Corporation | Hematology control composition including leukocyte analogs; and methods for their preparation and use |
US5512485A (en) * | 1992-02-24 | 1996-04-30 | Coulter Corporation | Hematology control composition including leukocyte analogs; and methods for their preparation and use |
US5529933A (en) * | 1992-02-24 | 1996-06-25 | Coulter Corporation | Suspension media for hematological composition and method for its use |
WO1993017330A1 (en) * | 1992-02-24 | 1993-09-02 | Coulter Corporation | Hematology control composition for leukocyte analogs; and methods for their preparation and use |
US6362003B1 (en) | 1992-02-24 | 2002-03-26 | Coulter Corporation | Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof |
US6509192B1 (en) | 1992-02-24 | 2003-01-21 | Coulter International Corp. | Quality control method |
WO1993017329A1 (en) * | 1992-02-24 | 1993-09-02 | Coulter Corporation | Suspension media for hematological composition and method for its use |
US5736402A (en) * | 1994-10-12 | 1998-04-07 | Research & Diagnostics Systems, Inc. | Reticulocyte assay control |
US5858789A (en) * | 1994-10-12 | 1999-01-12 | Research & Diagnostic Systems, Inc. | Method for making a reticulocyte assay control |
US5945340A (en) * | 1994-10-12 | 1999-08-31 | Research & Diagnostics Systems, Inc. | Reticulocyte assay control |
WO1996034291A1 (en) * | 1995-04-28 | 1996-10-31 | Coulter International Corp. | Quality control method of hematology instruments |
US5863799A (en) * | 1995-10-04 | 1999-01-26 | Hycor Biomedical, Inc. | Erythrocyte sedimentation rate control |
US5888822A (en) * | 1995-10-04 | 1999-03-30 | Hycor Biomedical Inc. | Erythrocyte sedimentation rate control |
US6331435B1 (en) | 1995-10-04 | 2001-12-18 | Streak Laboratories, Inc. | Erythrocyte sedimentation rate control |
US6051433A (en) * | 1995-10-04 | 2000-04-18 | Streck Laboratories, Inc. | Erythrocyte sedimentation rate control |
US5858790A (en) * | 1996-06-26 | 1999-01-12 | Abbott Laboratories | Hematology reference control and method of preparation |
US6187590B1 (en) | 1996-06-26 | 2001-02-13 | Abbott Laboratories | Hematology reference control and method of preparation |
US6017764A (en) * | 1997-02-04 | 2000-01-25 | Streck Laboratories, Inc. | Erythrocyte sedimentation rate control |
US5895760A (en) * | 1997-02-04 | 1999-04-20 | Hycor Biomedical, Inc. | Erythrocyte sedimentation rate control |
US6342391B1 (en) | 1997-02-04 | 2002-01-29 | Streck Laboratories, Inc. | Erythrocyte sedimentation rate control |
US5811303A (en) * | 1997-04-01 | 1998-09-22 | Streck Laboratories, Inc. | Quantitative buffy coat control composition |
US6146901A (en) * | 1997-06-16 | 2000-11-14 | Hematronix, Inc. | Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition |
US5994139A (en) * | 1998-04-07 | 1999-11-30 | Coulter International Corp. | Stable hematology control composition and method of use |
US6159682A (en) * | 1999-04-30 | 2000-12-12 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
US6124089A (en) * | 1999-04-30 | 2000-09-26 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
US6265148B1 (en) | 1999-04-30 | 2001-07-24 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
US6403377B1 (en) | 1999-08-20 | 2002-06-11 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6399388B1 (en) | 1999-08-20 | 2002-06-04 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6221668B1 (en) | 1999-08-20 | 2001-04-24 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
EP1212613A1 (en) * | 1999-08-20 | 2002-06-12 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6406915B2 (en) | 1999-08-20 | 2002-06-18 | Streck Laboratoreis, Inc. | Hematology control and system for multi-parameter hematology measurements |
EP1212613A4 (en) * | 1999-08-20 | 2005-09-21 | Streck Lab | HEMATOLOGICAL CONTROL AND SYSTEM FOR HEMATOLOGIC MUCH PARAMETER MEASUREMENTS |
US6200500B1 (en) | 1999-08-20 | 2001-03-13 | Streck Laboratories, Inc. | Hematology control and system for multi-parameter hematology measurements |
US6632676B1 (en) * | 1999-09-24 | 2003-10-14 | Clinical Diagnostic Solutions | Multi-purpose reagent system and method for enumeration of red blood cells, white blood cells and thrombocytes and differential determination of white blood cells |
US6444471B1 (en) | 1999-10-18 | 2002-09-03 | Research & Diagnostic Systems, Inc. | Reticulocyte containing complete blood control |
EP1307723A1 (en) * | 2000-06-12 | 2003-05-07 | Hematronix, Inc. | Hematology composition using preserved white blood cells |
EP1307723A4 (en) * | 2000-06-12 | 2006-01-04 | Bio Rad Laboratories | HEMATOLOGICAL COMPOSITION USING PRESERVED WHITE GLOBULES |
US6653063B2 (en) | 2000-06-12 | 2003-11-25 | Hematronix, Inc. | Hematology composition using preserved white blood cells in combination with source particles to simulate native white blood cells and method of making same |
US6531321B1 (en) | 2000-09-15 | 2003-03-11 | Streck Laboratories, Inc. | Blood control and system for erythrocyte sedimentation measurement |
US6569682B2 (en) | 2001-07-27 | 2003-05-27 | Coulter International Corp. | Hematology control product with increased closed vial stability |
US6759246B1 (en) | 2001-11-30 | 2004-07-06 | Research & Diagnostic Systems, Inc. | Hematology control composition including lymphocyte analogs and method for preparation and use |
US6723563B2 (en) | 2001-12-03 | 2004-04-20 | Streck Laboratories Inc. | Hematology reference control |
US6653137B2 (en) | 2001-12-03 | 2003-11-25 | Streck Laboratories Inc. | Hematology reference control |
US7176031B2 (en) | 2003-10-02 | 2007-02-13 | Beckman Coulter, Inc. | Reference control for optical measurement of nucleated red blood cells of a blood sample |
US20050074894A1 (en) * | 2003-10-02 | 2005-04-07 | Beckman Coulter, Inc. | Reference control for optical measurement of nucleated red blood cells of a blood sample |
US6962817B2 (en) | 2003-10-02 | 2005-11-08 | Beckman Coulter, Inc. | Reference control for optical measurement of nucleated red blood cells of a blood sample |
US20050266573A1 (en) * | 2003-10-02 | 2005-12-01 | Beckman Coulter, Inc. | Reference control for optical measurement of nucleated red blood cells of a blood sample |
US20050079623A1 (en) * | 2003-10-12 | 2005-04-14 | Beckman Coulter, Inc. | Method of using a reference control composition for measurement of nucleated red blood cells |
US7198953B2 (en) | 2003-10-12 | 2007-04-03 | Beckman Coulter, Inc. | Method of using a reference control composition for measurement of nucleated red blood cells |
US20050136409A1 (en) * | 2003-12-19 | 2005-06-23 | Beckman Coulter, Inc. | Hematology controls for reticulocytes and nucleated red blood cells |
US7195919B2 (en) | 2003-12-19 | 2007-03-27 | Beckman Coulter, Inc. | Hematology controls for reticulocytes and nucleated red blood cells |
US7135341B2 (en) | 2004-04-07 | 2006-11-14 | Beckman Coulter, Inc. | Reference control containing a nucleated red blood cell component |
US7285417B2 (en) | 2004-04-07 | 2007-10-23 | Beckman Coulter Inc. | Reference control containing a nucleated red blood cell component |
US20050227359A1 (en) * | 2004-04-07 | 2005-10-13 | Beckman Coulter, Inc. | Reference control containing a nucleated red blood cell component |
US20070072298A1 (en) * | 2004-04-07 | 2007-03-29 | Beckman Coulter, Inc. | Reference Control Containing a Nucleated Red Blood Cell Component |
US7109036B2 (en) | 2004-05-13 | 2006-09-19 | Beckman Coulter, Inc. | Hematology reference control containing an immature granulocyte component |
EP1766045A2 (en) * | 2004-05-13 | 2007-03-28 | Beckman Coulter, Inc. | Hematology reference control containing an immature granulocyte component |
US20070020611A1 (en) * | 2004-05-13 | 2007-01-25 | Beckman Coulter, Inc. | Hematology reference control containing an immature granulocyte component |
US20050255447A1 (en) * | 2004-05-13 | 2005-11-17 | Beckman Coulter, Inc. | Hematology reference control containing an immature granulocyte component |
US7393688B2 (en) | 2004-05-13 | 2008-07-01 | Beckman Coulter, Inc. | Method of using a hematology reference control for measurement of immature granulocytes |
EP1766045A4 (en) * | 2004-05-13 | 2009-06-03 | Beckman Coulter Inc | HEMATOLOGY REFERENCE CONTROL WITH AN UNREAL GRANULOCYTE COMPONENT |
US20060194191A1 (en) * | 2005-02-25 | 2006-08-31 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Processing method for the long-term stabilization of biological red blood cell volume |
US8029978B2 (en) | 2005-02-25 | 2011-10-04 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Processing method for the long-term stabilization of biological red blood cell volume |
US20060223187A1 (en) * | 2005-04-04 | 2006-10-05 | Bio-Rad Laboratories, Inc., A Corporation Of The State Of Delaware | Preparation of platelet analogs |
US7531357B2 (en) * | 2005-04-04 | 2009-05-12 | Bio-Rad Laboratories, Inc. | Preparation of platelet analogs |
CN1891815B (zh) * | 2005-07-04 | 2010-12-08 | 深圳迈瑞生物医疗电子股份有限公司 | 制备细胞模拟物的方法 |
CN100577797C (zh) * | 2005-07-04 | 2010-01-06 | 深圳迈瑞生物医疗电子股份有限公司 | 制备人淋巴细胞模拟物的方法 |
US7354767B2 (en) | 2006-03-16 | 2008-04-08 | Beckman Coulter, Inc. | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells |
US20070218558A1 (en) * | 2006-03-16 | 2007-09-20 | Beckman Coulter, Inc. | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells |
WO2008061073A2 (en) | 2006-11-14 | 2008-05-22 | Beckman Coulter, Inc. | Hematology linearity control composition system and method of use |
US20080113438A1 (en) * | 2006-11-14 | 2008-05-15 | Beckman Coulter, Inc. | Hematology Linearity Control Composition, System and Method of Use |
US7754487B2 (en) | 2006-11-14 | 2010-07-13 | Beckman Coulter, Inc. | Hematology linearity control composition, system and method of use |
US7659122B2 (en) * | 2007-05-24 | 2010-02-09 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Single population of simulated leukocyte granules, calibrators comprising the same and methods of preparing the same |
US20080293145A1 (en) * | 2007-05-24 | 2008-11-27 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Single population of simulated leukocyte granules, calibrators comprising the same and methods of preparing the same |
US20090258338A1 (en) * | 2008-04-15 | 2009-10-15 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Simulated 5-part differential leukocyte granules, the method for preparing the same and control products and calibrators comprising the same |
US8163470B2 (en) | 2008-04-15 | 2012-04-24 | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. | Simulated 5-part differential leukocyte granules, the method for preparing the same and control products and calibrators comprising the same |
CN101887059B (zh) * | 2009-05-11 | 2014-03-19 | 深圳迈瑞生物医疗电子股份有限公司 | 嗜酸性粒细胞模拟物、制备方法及全血质控物 |
CN101887059A (zh) * | 2009-05-11 | 2010-11-17 | 深圳迈瑞生物医疗电子股份有限公司 | 嗜酸性粒细胞模拟物、制备方法及全血质控物 |
CN102419365A (zh) * | 2011-08-24 | 2012-04-18 | 山东兰桥医学科技有限公司 | 一种三分类血液分析仪用标准物质的制备方法 |
CN102419365B (zh) * | 2011-08-24 | 2013-09-11 | 山东兰桥医学科技有限公司 | 一种三分类血液分析仪用标准物质的制备方法 |
CN103454410A (zh) * | 2012-05-30 | 2013-12-18 | 桂林优利特医疗电子有限公司 | 血液测试仪用生物安全质控物及其制备方法 |
CN103454410B (zh) * | 2012-05-30 | 2015-04-15 | 桂林优利特医疗电子有限公司 | 血液测试仪用生物安全质控物及其制备方法 |
WO2018022991A1 (en) | 2016-07-29 | 2018-02-01 | Streck, Inc. | Suspension composition for hematology analysis control |
US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
CN110770587A (zh) * | 2017-05-08 | 2020-02-07 | 拜克门寇尔特公司 | 用于裂解红细胞的组合物和方法 |
CN110770587B (zh) * | 2017-05-08 | 2023-10-20 | 拜克门寇尔特公司 | 用于裂解红细胞的组合物和方法 |
CN114657125A (zh) * | 2022-04-29 | 2022-06-24 | 中国科学院海洋研究所 | 鲨鱼单个核细胞的分离方法、鲨鱼稀释液及其用途 |
CN114657125B (zh) * | 2022-04-29 | 2023-08-08 | 中国科学院海洋研究所 | 鲨鱼单个核细胞的分离方法、鲨鱼稀释液及其用途 |
Also Published As
Publication number | Publication date |
---|---|
AU4352785A (en) | 1985-12-13 |
EP0181393A4 (en) | 1988-09-07 |
KR920010294B1 (ko) | 1992-11-21 |
WO1985005450A1 (en) | 1985-12-05 |
JPS61502210A (ja) | 1986-10-02 |
AU592754B2 (en) | 1990-01-25 |
DE3586619T2 (de) | 1993-04-22 |
EP0181393A1 (en) | 1986-05-21 |
ES543228A0 (es) | 1986-09-01 |
EP0181393B1 (en) | 1992-09-09 |
DE3586619D1 (de) | 1992-10-15 |
CA1249208A (en) | 1989-01-24 |
ES8609719A1 (es) | 1986-09-01 |
KR880700490A (ko) | 1988-03-15 |
JP2557837B2 (ja) | 1996-11-27 |
US5380664A (en) | 1995-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4704364A (en) | Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems | |
US5529933A (en) | Suspension media for hematological composition and method for its use | |
US5320964A (en) | Hematology control composition including leukocyte analogs; and methods for their preparation and use | |
US5672474A (en) | White blood cell hematology control | |
US7393688B2 (en) | Method of using a hematology reference control for measurement of immature granulocytes | |
US20050048656A1 (en) | Quality control method | |
US7354767B2 (en) | Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells | |
US6569682B2 (en) | Hematology control product with increased closed vial stability | |
US6759246B1 (en) | Hematology control composition including lymphocyte analogs and method for preparation and use | |
WO1992019966A1 (en) | White blood cell hematology control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COULTER ELECTRONICS, INC., 590 WEST 20TH ST., HIAL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:CARVER, FRANKLIN J.;GERULA, THEODORE J.;REEL/FRAME:004262/0681 Effective date: 19840516 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: COULTER INTERNATIONAL CORP., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COULTER CORPORATION;REEL/FRAME:011770/0789 Effective date: 19960709 |